Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
COVID-19
Ebola virus
Lassa virus
Nipah virus
infectious diseases
vaccines
zoonotic diseases
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
3
10
2022
medline:
16
12
2022
entrez:
2
10
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10-13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID-19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID-19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID-19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements-notably, in low-to-middle income countries-must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.
Identifiants
pubmed: 36183296
doi: 10.1111/nyas.14898
pmc: PMC9538336
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-225Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : U19 AI142790
Pays : United States
Informations de copyright
© 2022 New York Academy of Sciences.
Références
Novel 2019 coronavirus genome - SARS-CoV-2 coronavirus. (2020). Virological. https://virological.org/t/novel-2019-coronavirus-genome/319
Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. (2022). https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
National Institutes of Health. NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools. (2020). https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trials-network-test-covid-19-vaccines-other-prevention-tools
Marston, H. D., Paules, C. I., & Fauci, A. S. (2017). The critical role of biomedical research in pandemic preparedness. JAMA, 318, 1757-1758.
Graham, B. S., & Corbett, K. S. (2020). Prototype pathogen approach for pandemic preparedness: World on fire. Journal of Clinical Investigation, 130, 3348-3349.
Paules, C. I., Marston, H. D., & Fauci, A. S. (2020). Coronavirus infections-More than just the common cold. JAMA, 323, 707-708.
NIAID Pandemic Preparedness Plan.
Morens, D. M., & Fauci, A. S. (2020). Emerging pandemic diseases: How we got to COVID-19. Cell, 182, 1077-1092.
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020). COVID-19 and racial/ethnic disparities. JAMA, 323, 2466-2467.
Lopes, L., & Stokes, M. (2021). KFF. https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-media-and-misinformation/
G7 UK Presidency. G7 discuss 100 days mission to improve readiness for future pandemics. (2022). https://www.g7uk.org/g7-discuss-100-days-mission-to-improve-readiness-for-future-pandemics/
Saville, M., Cramer, J. P., Downham, M., Hacker, A., Lurie, N., Van Der Veken, L., Whelan, M., & Hatchett, R. (2022). Delivering pandemic vaccines in 100 days - What will it take? New England Journal of Medicine, 387, e3.
Gupta, N., Kaur, H., Yadav, P. D., Mukhopadhyay, L., Sahay, R. R., Kumar, A., Nyayanit, D. A., Shete, A. M., Patil, S., Majumdar, T., Rana, S., Gupta, S., Narayan, J., Vijay, N., Barde, P., Nataraj, G., Amrutha Kumari, B., Kumari, M. P., Biswas, D., … Iravane, J. (2021). Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India. Viruses, 13, 1782.
Deshpande, G. R., Yadav, P. D., Abraham, P., Nyayanit, D. A., Sapkal, G. N., Shete, A. M., Gupta, N., Vadrevu, K. M., Ella, R., Panda, S., & Bhargava, B. (2022). Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern. Journal of Travel Medicine, 29, taac039.
Pneumocystis pneumonia - Los Angeles. https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm
Institute of Medicine (US) Committee on Emerging Microbial Threats to Health. (1992). Emerging infections: Microbial threats to health in the United States. Washington, DC: National Academies Press (US).
International Health Regulations. (2022). https://www.who.int/health-topics/international-health-regulations
Carrion, M., & Madoff, L. C. (2017). ProMED-mail: 22 Years of digital surveillance of emerging infectious diseases. International Health, 9, 177-183.
Eurosurveillance Editorial Team. (2020). Note from the editors: Novel coronavirus (2019-nCoV). Eurosurveillance, 25, 200131e.
Madoff, L. C. (2004). ProMED-mail: An early warning system for emerging diseases. Clinical Infectious Diseases, 39, 227-232.
World Health Organization. (2008). A guide to establishing event-based surveillance. WHO Regional Office for the Western Pacific.
Olival, K. J., Cryan, P. M., Amman, B. R., Baric, R. S., Blehert, D. S., Brook, C. E., Calisher, C. H., Castle, K. T., Coleman, J. T. H., Daszak, P., Epstein, J. H., Field, H., Frick, W. F., Gilbert, A. T., Hayman, D. T. S., Ip, H. S., Karesh, W. B., Johnson, C. K., Kading, R. C., … Kingston, T. (2020). Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats. PLoS Pathogens, 16, e1008758.
Temmam, S., Vongphayloth, K., Baquero, E., Munier, S., Bonomi, M., Regnault, B., Douangboubpha, B., Karami, Y., Chrétien, D., Sanamxay, D., Xayaphet, V., Paphaphanh, P., Lacoste, V., Somlor, S., Lakeomany, K., Phommavanh, N., Pérot, P., Dehan, O., Amara, F., … Donati, F. (2022). Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. Nature, 604, 330-336.
Tan, C. W., Chia, W. N. I., Qin, X., Liu, P., Chen, M. I.-C., Tiu, C., Hu, Z., Chen, V. C.-W., Young, B. E., Sia, W. R., Tan, Y.-J., Foo, R., Yi, Y., Lye, D. C., Anderson, D. E., & Wang, L.-F. A. (2020). A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature Biotechnology, 38, 1073-1078.
Tan, C.-W., Chia, W.-N. I., Young, B. E., Zhu, F., Lim, B.-L., Sia, W.-R., Thein, T.-L., Chen, M. I.-C., Leo, Y.-S., Lye, D. C., & Wang, L.-F. A. (2021). Pan-Sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. New England Journal of Medicine, 385, 1401-1406.
Bergeri, I., Lewis, H. C., Subissi, L., Nardone, A., Valenciano, M., Cheng, B., Glonti, K., Williams, B., Abejirinde, I. O., Simniceanu, A., Cassini, A., Grant, R., Rodriguez, A., Vicari, A., Al Ariqi, L., Azim, T., Wijesinghe, P. R., Rajatonirina, S. C., Okeibunor, J. C., … Katz, M. (2022). Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza and Other Respiratory Viruses, 16, 7-13.
Bergeri, I., Whelan, M., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Ariqi, L. A., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., … Bobrovitz, N. (2022). Global epidemiology of SARS-CoV-2 infection: A systematic review and meta-analysis of standardized population-based seroprevalence studies. bioRxiv, 2021.12.14.21267791.
Lewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., Cao, C., Yanes-Lane, M., Herring, B. L., Talisuna, A., Ngoy, N., Balde, T., Clifton, D., Van Kerkhove, M. D., Buckeridge, D., … Bergeri, I. (2022). SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Global Health, 7(8), e008793.
Hegde, S. T., Salje, H., Sazzad, H. M. S., Hossain, M. J., Rahman, M., Daszak, P., Klena, J. D., Nichol, S. T., Luby, S. P., & Gurley, E. S. (2019). Using healthcare-seeking behaviour to estimate the number of Nipah outbreaks missed by hospital-based surveillance in Bangladesh. International Journal of Epidemiology, 48, 1219-1227.
Gurley, E. S., Hegde, S. T., Hossain, K., Sazzad, H. M. S., Hossain, M. J., Rahman, M., Sharker, M. A. Y., Salje, H., Islam, M. S., Epstein, J. H., Khan, S. U., Kilpatrick, A. M., Daszak, P., & Luby, S. P. (2017). Convergence of humans, bats, trees, and culture in Nipah virus transmission, Bangladesh. Emerging Infectious Diseases, 23, 1446-1453.
Epstein, J. H., Anthony, S. J., Islam, A., Kilpatrick, A. M., Ali Khan, S., Balkey, M. D., Ross, N., Smith, I., Zambrana-Torrelio, C., Tao, Y., Islam, A., Quan, P. L., Olival, K. J., Khan, M. S. U., Gurley, E. S., Hossein, M. J., Field, H. E., Fielder, M. D., Briese, T., … Daszak, P. (2020). Nipah virus dynamics in bats and implications for spillover to humans. Proceedings of the National Academy of Sciences of the United States of America, 117, 29190-29201.
Nikolay, B., Salje, H., Hossain, M. J., Khan, A. K. M. D., Sazzad, H. M. S., Rahman, M., Daszak, P., Ströher, U., Pulliam, J. R. C., Kilpatrick, A. M., Nichol, S. T., Klena, J. D., Sultana, S., Afroj, S., Luby, S. P., Cauchemez, S., & Gurley, E. S. (2019). Transmission of Nipah virus - 14 Years of investigations in Bangladesh. New England Journal of Medicine, 380, 1804-1814.
Kainulainen, M. H., Bergeron, E., Chatterjee, P., Chapman, A. P., Lee, J., Chida, A., Tang, X., Wharton, R. E., Mercer, K. B., Petway, M., Jenks, H. M., Flietstra, T. D., Schuh, A. J., Satheshkumar, P. S., Chaitram, J. M., Owen, S. M., Mcmullan, L. K., Flint, M., Finn, M. G., … Spiropoulou, C. F. (2021). High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay. Science Reports, 11, 12330.
Jacobsen, H., Sitaras, I., Jurgensmeyer, M., Mulders, M. N., Goldblatt, D., Feikin, D. R., Bar-Zeev, N., Higdon, M. M., & Knoll, M. D. (2022). Assessing the reliability of SARS-CoV-2 neutralization studies that use post-vaccination sera. Vaccines, 10, 850.
Fontes, C. M., Lipes, B. D., Liu, J., Agans, K. N., Yan, A., Shi, P., Cruz, D. F., Kelly, G., Luginbuhl, K. M., Joh, D. Y., Foster, S. L., Heggestad, J., Hucknall, A., Mikkelsen, M. H., Pieper, C. F., Horstmeyer, R. W., Geisbert, T. W., Gunn, M. D., & Chilkoti, A. (2021). Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR. Science Translational Medicine, 13, eabd9696.
Piorkowski, G., Jacquot, F., Quérat, G., Carbonnelle, C., Pannetier, D., Mentré, F., Raoul, H., & De Lamballerie, X. (2017). Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations. Antiviral Research, 140, 95-105.
Ebola haemorrhagic fever in Zaire, 1976. (1978). Bulletin of the World Health Organization, 56, 271-293.
Cross, R. W., Prasad, A. N., Woolsey, C. B., Agans, K. N., Borisevich, V., Dobias, N. S., Comer, J. E., Deer, D. J., Geisbert, J. B., Rasmussen, A. L., Lipkin, W. I., Fenton, K. A., & Geisbert, T. W. (2021). Natural history of nonhuman primates after conjunctival exposure to Ebola virus. bioRxiv, 2021.12.29.474476.
Stephenson, E. H., Larson, E. W., & Dominik, J. W. (1984). Effect of environmental factors on aerosol-induced Lassa virus infection. Journal of Medical Virology, 14, 295-303.
Downs, I. L., Shaia, C. I., Zeng, X., Johnson, J. C., Hensley, L., Saunders, D. L., Rossi, F., Cashman, K. A., Esham, H. L., Gregory, M. K., Pratt, W. D., Trefry, J. C., Everson, K. A., Larcom, C. B., Okwesili, A. C., Cardile, A. P., & Honko, A. (2020). Natural history of aerosol induced Lassa fever in non-human primates. Viruses, 12, 593.
Ibukun, F. I. (2020). Inter-lineage variation of Lassa virus glycoprotein epitopes: A challenge to Lassa virus vaccine development. Viruses, 12, 386.
Cross, R. W., Xu, R., Matassov, D., Hamm, S., Latham, T. E., Gerardi, C. S., Nowak, R. M., Geisbert, J. B., Ota-Setlik, A., Agans, K. N., Luckay, A., Witko, S. E., Soukieh, L., Deer, D. J., Mire, C. E., Feldmann, H., Happi, C., Fenton, K. A., Eldridge, J. H., & Geisbert, T. W. (2020). Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. Journal of Clinical Investigation, 130, 539-551.
Mcelroy, A. K., Akondy, R. S., Davis, C. W., Ellebedy, A. H., Mehta, A. K., Kraft, C. S., Lyon, G. M., Ribner, B. S., Varkey, J., Sidney, J., Sette, A., Campbell, S., Ströher, U., Damon, I., Nichol, S. T., Spiropoulou, C. F., & Ahmed, R. (2015). Human Ebola virus infection results in substantial immune activation. Proceedings of the National Academy of Sciences of the United States of America, 112, 4719-4724.
Ruibal, P., Oestereich, L., Lüdtke, A., Becker-Ziaja, B., Wozniak, D. M., Kerber, R., Korva, M., Cabeza-Cabrerizo, M., Bore, J. A., Koundouno, F. R., Duraffour, S., Weller, R., Thorenz, A., Cimini, E., Viola, D., Agrati, C., Repits, J., Afrough, B., Cowley, L. A., … Ngabo, D. (2016). Unique human immune signature of Ebola virus disease in Guinea. Nature, 533, 100-104.
Speranza, E., Ruibal, P., Port, J. R., Feng, F., Burkhardt, L., Grundhoff, A., Günther, S., Oestereich, L., Hiscox, J. A., Connor, J. H., & Muñoz-Fontela, C. (2018). T-cell receptor diversity and the control of T-cell homeostasis mark Ebola virus disease survival in humans. Journal of Infectious Diseases, 218, S508-S518.
Lüdtke, A., Ruibal, P., Wozniak, D. M., Pallasch, E., Wurr, S., Bockholt, S., Gómez-Medina, S., Qiu, X., Kobinger, G. P., Rodríguez, E., Günther, S., Krasemann, S., Idoyaga, J., Oestereich, L., & Muñoz-Fontela, C. (2017). Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Science Reports, 7, 43776.
Escudero-Pérez, B., Ruibal, P., Rottstegge, M., Lüdtke, A., Port, J. R., Hartmann, K., Gómez-Medina, S., Müller-Guhl, J., Nelson, E. V., Krasemann, S., Rodríguez, E., & Muñoz-Fontela, C. (2019). Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight, 4, 126070.
Gostic, K. M., Ambrose, M., Worobey, M., & Lloyd-Smith, J. O. (2016). Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science, 354, 722-726.
Carreño, J. M., Strohmeier, S., Kirkpatrick Roubidoux, E., Hai, R., Palese, P., & Krammer, F. (2020). H1 hemagglutinin priming provides long-lasting heterosubtypic immunity against H5N1 challenge in the mouse model. mBio, 11, e02090-20.
Munster, V. J., Feldmann, F., Williamson, B. N., Van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., Avanzato, V. A., Rosenke, R., Hanley, P. W., Saturday, G., Scott, D., Fischer, E. R., & De Wit, E. (2020). Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature, 585, 268-272.
Williamson, B. N., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D. P., Schulz, J., Van Doremalen, N., Leighton, I., Yinda, C. K., Pérez-Pérez, L., Okumura, A., Lovaglio, J., Hanley, P. W., Saturday, G., Bosio, C. M., Anzick, S., Barbian, K., Cihlar, T., Martens, C., … Scott, D. P. (2020). Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature, 585, 273-276.
Van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., Feldmann, F., Allen, E. R., Sharpe, H., Schulz, J., Holbrook, M., Okumura, A., Meade-White, K., Pérez-Pérez, L., Edwards, N. J., … Wright, D. (2020). ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 586, 578-582.
Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., Qin, C., Crozier, I., Dallmeier, K., De Waal, L., De Wit, E., Delang, L., Dohm, E., Duprex, W. P., Falzarano, D., … Finch, C. L. (2020). Animal models for COVID-19. Nature, 586, 509-515.
Speranza, E., Purushotham, J. N., Port, J. R., Schwarz, B., Flagg, M., Williamson, B. N., Feldmann, F., Singh, M., Pérez-Pérez, L., Sturdevant, G. L., Roberts, L. M., Carmody, A., Schulz, J. E., van Doremalen, N., Okumura, A., Lovaglio, J., Hanley, P. W., Shaia, C., Germain, R. N., … de Wit, E. (2022). Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. Life Science Alliance, 5, e202101314.
Ang, B. S. P., Lim, T. C. C., & Wang, L. (2018). Nipah virus infection. Journal of Clinical Microbiology, 56, e01875-17.
de Wit, E., Bushmaker, T., Scott, D., Feldmann, H., & Munster, V. J. (2011). Nipah virus transmission in a hamster model. PLoS Neglected Tropical Diseases, 5, e1432.
de Wit, E., Prescott, J., Falzarano, D., Bushmaker, T., Scott, D., Feldmann, H., & Munste, V. J. (2014). Foodborne transmission of Nipah virus in Syrian hamsters. PLoS Pathogens, 10, e1004001.
Munster, V. J., Prescott, J. B., Bushmaker, T., Long, D., Rosenke, R., Thomas, T., Scott, D., Fischer, E. R., Feldmann, H., & De Wit, E. (2012). Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Science Reports, 2, 736.
Lo, M. K., Feldmann, F., Gary, J. M., Jordan, R., Bannister, R., Cronin, J., Patel, N. R., Klena, J. D., Nichol, S. T., Cihlar, T., Zaki, S. R., Feldmann, H., Spiropoulou, C. F., & De Wit, E. (2019). Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Science Translational Medicine, 11, eaau9242.
Zohar, T., & Alter, G. (2020). Dissecting antibody-mediated protection against SARS-CoV-2. Nature Reviews Immunology, 20, 392-394.
Bahnan, W., Wrighton, S., Sundwall, M., Bläckberg, A., Larsson, O., Höglund, U., Khakzad, H., Godzwon, M., Walle, M., Elder, E., Strand, A. S., Happonen, L., André, O., Ahnlide, J. K., Hellmark, T., Wendel-Hansen, V., Wallin, R. P. A., Malmstöm, J., Malmström, L., … Nordenfelt, P. (2021). Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2. Frontiers in Immunology, 12, 808932.
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., Shawa, I., Adams, A. C., Van Naarden, J., Custer, K. L., Shen, L., Durante, M., Oakley, G., Schade, A. E., Sabo, J., … Skovronsky, D. M. (2021). SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. New England Journal of Medicine, 384, 229-237.
Casadevall, A., Joyner, M. J., & Pirofski, L.-A. (2021). Neutralizing antibody LY-CoV555 for outpatient Covid-19. New England Journal of Medicine, 384, 189.
Hastie, K. M., Li, H., Bedinger, D., Schendel, S. L., Dennison, S. M., Li, K., Rayaprolu, V., Yu, X., Mann, C., Zandonatti, M., Diaz Avalos, R., Zyla, D., Buck, T., Hui, S., Shaffer, K., Hariharan, C., Yin, J., Olmedillas, E., Enriquez, A., … Parekh, D. (2021). Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science, 374, 472-478.
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Finkin, S., Hägglöf, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., … Bjorkman, P. J. (2020). Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell, 182, 828-842.e16.e16.
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F., Davies, H., Ulaszewska, M., Belij-Rammerstorfer, S., Morris, S., Krebs, A.-S., Dejnirattisai, W., Mongkolsapaya, J., Supasa, P., Screaton, G. R., Green, C. M., … Crispin, M. (2021). Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. ACS Central Science, 7, 594-602.
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E. A., Collins, A. M., Cutland, C. L., Darton, T. C., Dheda, K., Dold, C., … Duncan, C. J. A. (2021). Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet, 397, 881-891.
Bhuyan, P., Medin, J., Da Silva, H. G., Yadavalli, M., Shankar, N. K., Mullerova, H., Arnold, M., & Nord, M. (2021). Very rare thrombosis with thrombocytopenia after second AZD1222 dose: A global safety database analysis. Lancet, 398, 577-578.
Soboleva, K., Shankar, N. K., Yadavalli, M., Ferreira, C., Foskett, N., Putsepp, K., Ferstenberg, L. B., Nord, M., Da Silva, H. G., & Bhuyan, P. (2022). Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination. Lancet Global Health, 10, e33-e34.
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C. N. J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M. (2021). Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New England Journal of Medicine, 385, 585-594.
Warimwe, G. M., Gesharisha, J., Carr, B. V., Otieno, S., Otingah, K., Wright, D., Charleston, B., Okoth, E., Elena, L.-G., Lorenzo, G., Ayman, E.-B., Alharbi, N. K., Al-Dubaib, M. A., Brun, A., Gilbert, S. C., Nene, V., & Hill, A. V. S. (2016). Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. Science Reports, 6, 20617.
van Doremalen, N., Avanzato, V. A., Feldmann, F., Schulz, J. E., Haddock, E., Okumura, A., Lovaglio, J., Hanley, P. W., Cordova, K., Saturday, G., Lambe, T., Gilbert, S. C., & Munster, V. J. (2021). ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys. bioRxiv, 2021.07.20.452991.
Fischer, R. J., Purushotham, J. N., Van Doremalen, N., Sebastian, S., Meade-White, K., Cordova, K., Letko, M., Jeremiah Matson, M., Feldmann, F., Haddock, E., Lacasse, R., Saturday, G., Lambe, T., Gilbert, S. C., & Munster, V. J. (2021). ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines, 6, 32.
van Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R. J., Yinda, C. K., Thakur, N., Newman, J., Ulaszewska, M., Belij-Rammerstorfer, S., Saturday, G., Spencer, A. J., Bailey, D., Gilbert, S. C., Lambe, T., & Munster, V. J. (2022). Efficacy of ChAdOx1 vaccines against SARS-CoV-2 variants of concern Beta, Delta and Omicron in the Syrian hamster model. Research Square, rs-3.
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., Dipiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Hutchinson, G. B. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 586, 567-571.
Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y. I., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., Yang, Z.-Y., Chen, X., Becker, M. M., Freeman, M., Vogel, L., Johnson, J. C., Olinger, G., Todd, J. P., Bagci, U., … Graham, B. S. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communication, 6, 7712.
Mclellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., Kumar, A., Modjarrad, K., Zheng, Z., Zhao, M., Xia, N., Kwong, P. D., & Graham, B. S. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340, 1113-1117.
Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., Mclellan, J. S., & Ward, A. B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature, 531, 118-121.
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & Mclellan, J. S. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 114, E7348-E7357.
Buck, T. K., Enriquez, A. S., Schendel, S. L., Zandonatti, M. A., Harkins, S. S., Li, H., Moon-Walker, A., Robinson, J. E., Branco, L. M., Garry, R. F., Saphire, E. O., & Hastie, K. M. (2022). Neutralizing antibodies against Lassa virus lineage I. mBio, 13(4), e0127822.
Enriquez, A. S., Buck, T. K., Li, H., Norris, M. J., Moon-Walker, A., Zandonatti, M. A., Harkins, S. S., Robinson, J. E., Branco, L. M., Garry, R. F., Saphire, E. O., & Hastie, K. M. (2022). Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Reports, 39, 110841.
Hastie, K. M., Cross, R. W., Harkins, S. S., Zandonatti, M. A., Koval, A. P., Heinrich, M. L., Rowland, M. M., Robinson, J. E., Geisbert, T. W., Garry, R. F., Branco, L. M., & Saphire, E. O. (2019). Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell, 178, 1004-1015.e14.
Mire, C. E., Cross, R. W., Geisbert, J. B., Borisevich, V., Agans, K. N., Deer, D. J., Heinrich, M. L., Rowland, M. M., Goba, A., Momoh, M., Boisen, M. L., Grant, D. S., Fullah, M., Khan, S. H., Fenton, K. A., Robinson, J. E., Branco, L. M., Garry, R. F., & Geisbert, T. W. (2017). Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nature Medicine, 23, 1146-1149.
Cross, R. W., Hastie, K. M., Mire, C. E., Robinson, J. E., Geisbert, T. W., Branco, L. M., Ollmann Saphire, E., & Garry, R. F. (2019). Antibody therapy for Lassa fever. Current Opinion in Virology, 37, 97-104.
Carnec, X., Mateo, M., Page, A., Reynard, S. P., Hortion, J., Picard, C., Yekwa, E., Barrot, L., Barron, S. P., Vallve, A., Raoul, H., Carbonnelle, C., Ferron, F. O., & Baize, S. (2018). A vaccine platform against arenaviruses based on a recombinant hyperattenuated Mopeia virus expressing heterologous glycoproteins. Journal of Virology, 92, e02230-17.
Mateo, M., Reynard, S. P., Carnec, X., Journeaux, A., Baillet, N., Schaeffer, J., Picard, C., Legras-Lachuer, C., Allan, R., Perthame, E., Hillion, K.-H., Pietrosemoli, N., Dillies, M.-A., Barrot, L., Vallve, A., Barron, S. P., Fellmann, L., Gaillard, J.-C., Armengaud, J., … Baize, S. (2019). Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Science Translational Medicine, 11, eaaw3163.
Bugin, K., & Woodcock, J. (2021). Trends in COVID-19 therapeutic clinical trials. Nature Reviews Drug Discovery, 20, 254-255.
Reis, G., Dos Santos Moreira-Silva, E. A., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., Dos Santos, C. V. Q., De Souza Campos, V. H., Nogueira, A. M. R., De Almeida, A. P. F. G., Callegari, E. D., De Figueiredo Neto, A. D., Savassi, L. C. A. M., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., Harari, O., Forrest, J. I., Ruton, H., … Sprague, S. (2022). Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Global Health, 10, e42-e51.
Eiger BioPharmaceuticals. (2022). Eiger's single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in a predominantly vaccinated population in phase 3 TOGETHER study. https://ir.eigerbio.com/news-releases/news-release-details/eigers-single-dose-peginterferon-lambda-covid-19-reduced-risk
Reis, G., Silva, E. A. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., Dos Santos, C. V. Q., Campos, V. H. S., Nogueira, A. M. R., De Almeida, A. P. F. G., Callegari, E. D., Neto, A. D. F., Savassi, L. C. M., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., Harari, O., Forrest, J. I., Ruton, H., … Sprague, S. (2022). Effect of early treatment with ivermectin among patients with Covid-19. New England Journal of Medicine, 386, 1721-1731.
Veru Inc. (2022). Veru reports that independent data monitoring committee for the phase 3 sabizabulin COVID-19 clinical study recommends continuing study as planned. https://verupharma.gcs-web.com/news-releases/news-release-details/veru-reports-independent-data-monitoring-committee-phase-3